Related Experiment Video
Updated: Jul 30, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Tale of two hearts: a TNNT2 hypertrophic cardiomyopathy case report
Justin H Pham1, John R Giudicessi2,3, Marysia S Tweet2
1Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, MN, United States.
Insights
Hypertrophic cardiomyopathy (HCM) in a mother and daughter showed varied disease severity despite the same genetic mutation. This highlights incomplete penetrance and variable expressivity in HCM patient care.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Hypertrophic cardiomyopathy (HCM) is a genetic heart condition often caused by mutations in sarcomeric proteins.
- Cardiac Troponin T (TNNT2) gene mutations are a known cause of inherited HCM.
- Disease presentation in HCM can vary significantly among affected individuals.
Abstract:
Hypertrophic cardiomyopathy (HCM) is a heritable cardiomyopathy that is predominantly caused by pathogenic mutations in sarcomeric proteins. Here we report two individuals, a mother and her daughter, both heterozygous carriers of the same HCM-causing mutation in cardiac Troponin T (TNNT2). Despite sharing an identical pathogenic variant, the two individuals had very different manifestations of the disease. While one patient presented with sudden cardiac death, recurrent tachyarrhythmia, and findings of massive left ventricular hypertrophy, the other patient manifested with extensive abnormal myocardial delayed enhancement despite normal ventricular wall thickness and has remained relatively asymptomatic. Recognition of the marked incomplete penetrance and variable expressivity possible in a single TNNT2-positive family has potential to guide HCM patient care.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Heart Failure II: Pathophysiology

